Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans

STX209 is an exploratory drug comprising the single, active R-enantiomer of baclofen which is in later stage clinical trials for the treatment of fragile x syndrome (FXS) and autism spectrum disorders (ASD). New clinical data in this article on the metabolism and pharmacokinetics of the R- and S-ena...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanchez-Ponce, Raymundo, Wang, Li-Quan, Lu, Wei, von Hehn, Jana, Cherubini, Maryann, Rush, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901214/
https://www.ncbi.nlm.nih.gov/pubmed/24957649
http://dx.doi.org/10.3390/metabo2030596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901214/
https://www.ncbi.nlm.nih.gov/pubmed/24957649
http://dx.doi.org/10.3390/metabo2030596

Ejemplares similares